Benchmark Reiterates Speculative Buy Rating for CytoMed Therapeutics (NASDAQ:GDTC)

CytoMed Therapeutics (NASDAQ:GDTC)‘s stock had its “speculative buy” rating reaffirmed by equities researchers at Benchmark in a research report issued on Thursday, Benzinga reports. They currently have a $5.00 price target on the stock. Benchmark’s target price would indicate a potential upside of 145.10% from the company’s current price.

CytoMed Therapeutics Trading Up 1.5 %

Shares of NASDAQ GDTC opened at $2.04 on Thursday. CytoMed Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $5.50. The stock has a fifty day moving average of $1.64 and a 200-day moving average of $1.92.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.